Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

01 January 2008

Generic products – requirements for drug registration

P. K. Kunicki

Ann Transplant 2008; 13(1): 30-30 :: ID: 880184

Abstract

European Regulatory Agencies e.g. EMEA define what generic product is. It is a medicinal product essentially similar to an original product i.e. which has the same qualitative and quantitative composition in active substances, the same pharmaceutical form, and whose bioequivalence with the reference product has been demonstrated by appropriate bioavailability studies. It means that generic should be almost identical to an innovator product and everyone knows it is almost impossible. Therefore, precise quantitative criteria are necessary to set the borderline for dissimilarity that could be accepted regarding drug safety and efficacy. The majority of generics of generally acting drugs require for registration purposes bioequivalence studies thus this is statistical acceptance for bioavailability parameters what creates the door onto a market. The simplest study design is: single dose, 2-period, 2-sequence, crossover bioequivalence study in young (18-55 y.) healthy volunteers in fasting state, if necessary the design becomes more complex including food effect testing and multiple dosing. In general, Registration Agencies require for proving average bioequivalence, 90% confidence intervals for AUC and Cmax ratios (test/reference) within 0.80-1.25 for log-transformed data. That means generic product is acceptable differing up to 20% from the reference product in 90% of subjects. That door seems to be too wide for a few percent of drugs which are "narrow therapeutic index" and/or "critical dose" drugs. It is obvious that because of clear economic reasons, the manufacturer introducing generic drug is doing only what is necessary for successful registration of the product i.e. the simplest, the shortest and the cheapest study. Such a situation may provoke the collision of interest between patient's safety and interest of generic companies. Therefore the task for Registration Agencies is to create and to obey clear rules for introducing generic products on the market taking into account that bioequivalence requirements must be related to specifi c drug.

Keywords: intellectual disability (mental retardation), Metabolism syndrome, Transplantation

Add Comment 0 Comments

In Press

07 Mar 2024 : Original article  

Outcomes of Renal Transplantation in ANCA-Associated Vasculitis

Ann Transplant In Press; DOI: 10.12659/AOT.943433  

08 Mar 2024 : Original article  

Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persisten...

Ann Transplant In Press; DOI: 10.12659/AOT.943532  

14 Mar 2024 : Original article  

Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort Study

Ann Transplant In Press; DOI: 10.12659/AOT.943652  

14 Mar 2024 : Case report  

Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo ...

Ann Transplant In Press; DOI: 10.12659/AOT.942358  

Most Viewed Current Articles

05 Apr 2022 : Original article  

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

12 Jan 2022 : Original article  

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

22 Nov 2022 : Original article  

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358